Exchange: NYSEArca·Updated 07:30 PM EDT

AVDE News

News
all
press releases
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
The FDA has told Novo that its review of the biologics license application is still underway and has not given a new date for a decision.
Stocktwits
Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long
The FDA has told Novo that its review of the biologics license application is still underway and has not given a new date for a decision.
Stocktwits
More News
NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip
NVO stock is down 11% this week, on track for its worst week since late February if losses hold.
Stocktwits
NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen
The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.
Stocktwits
AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus
A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said.
Stocktwits
Want to Tap Global Growth? These Equity ETFs Could Benefit
Seeking growth beyond U.S. borders? Global equity ETFs could offer diversification and exposure to attractive opportunities across international markets.
Zacks
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future
Novo now expects underlying sales and operating profit in the range of 0% to –6% for the year.
Stocktwits
NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court
The Danish drugmaker reported on Friday that its experimental cardiovascular drug ziltivekimab failed a key late-stage trial, marking a significant pipeline setback in its efforts to diversify beyond blockbuster obesity and diabetes treatments.
Stocktwits
Global ETFs to Diversify as Tech Weakness Weighs on Markets
The AI trade is under pressure as a semiconductor slump and financing concerns rattle markets, making global ETFs worth a closer look.
Zacks
NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart
Oral Wegovy is now cleared in all EU member states.
Stocktwits
Global ETFs Back in the Spotlight on Macroeconomic Tailwinds
Easing geopolitical tensions, a softer dollar and improving risk appetite are reviving interest in global equity ETFs.
Zacks

Advertisement|Remove ads.